Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan.
We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80 mg/m2, followed by CDDP 75 mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
Division of Medical Oncology and Hematology, Cancer Institute Hospital, Koto-ku, Tokyo 135-8550, Japan. n-mori@md.okayama-u.ac.jp
Hisakazu
H
Nishimori
Shunji
S
Takahashi
Katsuyuki
K
Kiura
Daisuke
D
Ennishi
Takayuki
T
Kobayashi
Koji
K
Sano
Eiji
E
Shinozaki
Masahiro
M
Yokoyama
Yuko
Y
Mishima
Yasuhito
Y
Terui
Keisho
K
Chin
Nobuyuki
N
Mizunuma
Yoshinori
Y
Ito
Seiichiro
S
Nishimura
Kengo
K
Takeuchi
Yuichi
Y
Ishikawa
Masahiko
M
Oguchi
Mitsune
M
Tanimoto
Kiyohiko
K
Hatake
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced; D007564:Japan; D008297:Male; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin